ACET - NASDAQ
Adicet Bio, Inc.
$8.15
+4.1%Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
At a Glance
Live SnapshotAdicet Bio, Inc. Management Team
Mr. Chen Schor BA, CPA, M.B.A.
Chief Executive Officer, President & Director
Compensation
$888,012
Mr. Brian Nicholas Harvey
Chief Financial Officer
Compensation
$611,141
Ms. Amy Locke
Chief Human Resource Officer
Dr. Julie Maltzman M.D.
Chief Medical Officer
Dr. Donald Healey Ph.D.
Chief Technology Officer
Compensation
$606,337
Dr. Aya Jakobovits Ph.D.
Founder & Independent Director
Compensation
$45,000
Dr. Blake Aftab Ph.D.
Senior Vice President & Chief Scientific Officer
Compensation
$693,817
Adicet Bio, Inc. Insider Positioning
During the last 12 months, insiders have purchased $5.12M and sold $191K worth of ACET shares, resulting in $4.93M of net buying activity.
3 Months
0
0.00
29.3K
191.45K
-191K
-$191K
3-6 Months
223.6K
1.60M
0
0.00
+1.6M
+$1.60M
6-9 Months
3.5M
3.50M
0
0.00
+3.5M
+$3.50M
9-12 Months
26.4K
20.59K
0
0.00
+21K
+$21K
Top Buyers
Orbimed Advisors Llc
10 Percent Owner
$3.50M
Ra Capital Management, L.P.
10 Percent Owner
$1.60M
Klickstein Lloyd
Director
$21K
Top Sellers
Orbimed Advisors Llc
10 Percent Owner
$191K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.93M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
ACET - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | November 17, 2025 | December 19, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | April 23, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | April 18, 2023 | December 31, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 18, 2021 | April 27, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 27, 2020 | May 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 27, 2019 | May 08, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.